A steep decline in Ozempic maker Novo Nordisk’s share price has sent consumer confidence in Denmark to a three-month low.

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

Novo Nordisk has announced a sweeping reduction in the cost of its blockbuster diabetes drug Ozempic, cutting the monthly ...

The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump demanded cheaper drugs for ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

Danish group’s shares rise after it cuts cost for blockbuster diabetes and weight-loss drug for patients without insurance ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk said it would begin selling its Type 2 diabetes treatment Ozempic directly to consumers at $499 per month, half ...

Lowe’s tops Home Depot with an $8.8 billion buyout deal and an earnings beat Abrupt Antarctic climate shifts could lead to ...

Novo Nordisk revealed on Monday that US patients can now receive a month’s supply of Ozempic, a highly effective diabetes ...